Active	Status	Sponsor type	Region	Phase	Filter
8 Active 63 Inactive 71 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cortes, Jorge
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage	Recruiting	3	450	US	DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine	Delta-Fly Pharma, Inc.	Leukemia, Myeloid, Acute	12/22	12/22
NCT00930540: DB-67 in Myelodysplastic Syndrome (MDS)	Active, not recruiting	2	25	US	AR-67 (DB-67), DB-67, 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin	M.D. Anderson Cancer Center, Arno Therapeutics	Myelodysplastic Syndrome	12/15
ASC4MORE, NCT03578367 / 2018-001594-24: Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)	Active, not recruiting	2	104	Europe, Canada, US, RoW	Asciminib add-on, ABL001 (asciminib), Imatinib, STI571, Nilotinib, AMN107, Asciminib single agent	Novartis Pharmaceuticals	CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases	11/21	02/25
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia	Recruiting	2	182	US	asciminib, ABL001	Novartis Pharmaceuticals	Chronic Myelogenous Leukemia - Chronic Phase	02/26	02/27
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies	Active, not recruiting	1/2	122	Europe, US, RoW	Vodobatinib (K0706) capsules	Sun Pharma Advanced Research Company Limited	Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)	08/26	08/26
NCT03038230: MCLA-117 in Acute Myelogenous Leukemia Data from trial for AML at EHA 2020 Jun 2020 - Jun 2020: Data from trial for AML at EHA 2020 Initial data in AML May 2020 - May 2020: Initial data in AML Planned clinical update Dec 2018 - Dec 2018: Planned clinical update More	Active, not recruiting	1	62	Europe, US	MCLA-117 bispecific antibody, bispecific, human bispecific common light chain, bispecific IgG1 targeting CLEC12A and CD3	Merus N.V.	Acute Myelogenous Leukemia, Acute Myeloid Leukemia	07/21	07/21
Wilcox, Cecilia
No trials found